Integrase inhibitors do not increase the risk of major cardiovascular events such as a heart attack or stroke compared to other types of antiretroviral drug over four years of follow-up, a large multinational study reports in Lancet HIV.
The study confirms research from the Swiss HIV Cohort, which used a similar method of calculating the risk, and contradicts the findings of a study of people with HIV in Europe and Australia which found a raised risk during the first two years on treatment.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
Infectious Disease Special Edition: Immunomodulators in patients living with HIV
-
TheBodyPro: A new study on HIV, hypertension, and pregnancy is about a lot more than it seems
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.